Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 20

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 20
---
and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements
of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology
such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,”
“objective,” “plan,” “predict,” “potential,” “positioned,” “seek,”
“should,” “target,” “will,” “would,” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking
statements include, but are not limited to, statements about:

| ● | the ability of our pre-clinical and any future clinical trials to demonstrate safety and efficacy of our future product candidates, and other positive results; |

| ● | the timing and focus of our future preclinical studies and clinical trials, and the reporting of data from those studies and trials; |

| ● | the size of the market opportunity for our future product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; |

| ● | the success of competing therapies that are or may become available; |

| ● | the beneficial characteristics, safety, efficacy and therapeutic effects of our future product candidates, as well as the potential healthcare costs saved through utilizing our future product candidates; |

| ● | the ability of our future product candidates to address needs not currently addressed by the psychedelic industry; |

| ● | the ability of our future product candidates to address needs not currently addressed by the psychedelic industry; |

| ● | our ability to obtain and maintain regulatory approval of our future product candidates; |

| ● | our plans relating to the further development of our future product candidates, including additional disease states or indications we may pursue; |

| ● | existing regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; |

| ● | the ability of our management team to oversee our drug research programs; |

| ● | the need to hire additional personnel and our ability to attract and retain such personnel; |

<div align='center'>8</div>

| ● | our estimates regarding expenses